

Draft NTP Technical Report TR582 on Vinylidene Chloride in F344/N Rats and B6C3F1/N Mice

(Inhalation Studies)

$$c = c + C$$

Michael Wyde, Ph.D.

National Institute of Environmental Health Sciences

NTP Technical Reports Peer Review Meeting October 29, 2013



Background

- Nominated by Agency for Toxic Substances and Disease Registry (ATSDR) based on insufficient critical information concerning health effects
- Used as intermediate in organic synthesis reactions and in production of polyvinylidene chloride polymers and copolymers
- Occupational exposure via inhalation or dermal contact; primary source of environmental contamination through air emissions and effluent waters from processing facilities
 - Common in household products, artificial turf, pipes, in lacquer resins and latex, and flame-resistant carpet backing
- US annual production estimated at 79,000 tons (2003)
- ACGIH Threshold Limit Value (TLV) 5 ppm; EPA Category C carcinogen – a possible human carcinogen

NTP Program of Study for VDC

- 2-Week inhalation toxicity studies in male and female Fisher 344/N rats and B6C3F₁/N mice
- 3-Month inhalation studies in rats and mice
- 2-year inhalation studies in rats and in mice
- Genotoxicity testing
 - Salmonella, Drosophila reciprocal translocation/sexlinked recessive lethal, mouse lymphoma, micronucleus

Genetic Toxicity Test Results for Vinylidene Chloride

| Test | Result |
|---|-------------------------------------|
| Bacterial Mutagenicity | Negative (+/- S9) |
| Mouse Lymphoma Cell Mutagenicity | Positive (+ S9) Equivocal (- S9) |
| Drosophila Sex-Linked Recessive Lethals | Negative |
| Erythrocyte Micronucleus | Negative (♂/♀ Mice) |

Vinylidene Chloride 2-Week Studies

- Male and female F344/N rats (up to 400 ppm)
 - No survival in males or females at 200 or 400 ppm
 - Decreased body weight gain in 100 ppm females
 - Increased kidney weights and centrilobular hepatocyte necrosis and cytoplasmic alteration in males and females
- Male and female B6C3F1/N mice (up to 400 ppm)
 - No survival in females at 200 or 400 ppm, or in males at ≥ 100 ppm
 - Decreased body weight gain in 25 and 50 ppm males
 - Increased lung weight in females; increased liver weights in males and females
 - Liver necrosis in 100 ppm males and females and regeneration in 100 ppm females
 - Tubule necrosis, regeneration, granular casts in male kidney (25-50ppm)

3-Month Studies

- Male and female F344/N rats and B6C3F1/N mice (n=10)
- Exposure concentrations
 - Rats: 0, 6.25, 12.5, 25, 50, and 100 ppm
 - Female mice: 0, 6.25, 12.5, 25, 50, and 100 ppm
 - Male mice: 0, 6.25, 12.5, 25, and 50 ppm
- 6 hours a day, 5 days a week

3-Month Results in Rats

- No effect on mortality, body weight gain, hematological indices in males or females
- Increases in kidney weights in females ≥12.5 ppm
- In the liver, cytoplasmic vacuolization (females ≥50 ppm) and centrilobular cytoplasmic alteration (males ≥12.5 ppm) were observed
 - Transient increase in sorbitol dehydrogenase and alanine aminotransferase
- Increased olfactory epithelium atrophy, mineralization, and necrosis, and turbinate atrophy in male and females
 - Nasal lesions were not considered to be sufficient to preclude 100 ppm as exposure concentration for the chronic rat studies
 - Selected 0, 25, 50, and 100 ppm for chronic inhalation studies in rats

3-Month Results in Mice

- Decreased survival in 50 ppm males and 100 ppm females
- Lower mean body weight in all exposed females (9-18%) and ≥12.5 ppm males (10-16%)
- Exposure concentration-related decreases in red blood cell indices, males affected at lower exposure concentrations than females
- Increased liver weight in females at ≥12.5 ppm; increased kidney and lung weights in 100 ppm females
- Lesions observed in 100 ppm females:
 - <u>Liver</u> necrosis, centrilobular hypertrophy; <u>lung</u> histiocytic inflammation and necrosis of the bronchus epithelium; respiratory epithelium necrosis and turbinate atrophy in <u>nose</u>
- Increased incidence of squamous metaplasia of the respiratory epithelium of the larynx of ≥ 50 ppm females and 50 ppm males
- Increased incidence and severity of nephropathy in males at ≥12.5 ppm

Exposure Selection for Chronic Studies in Mice

- Chronic exposure concentration selection primarily dependent on survival and body weight reductions
 - Increased mortality in males at 50 ppm; only observed decreased body weight in males at 25 ppm (absence of other overt toxicity)
 - Smaller decrease in body weight in 6.25, 12.5, and 25 ppm females (9-12%) compared to the 50 ppm group (18%)
 - No treatment-related histopathology
- Selected 0, 6.25, 12.5, and 25 ppm for chronic inhalation studies in mice


Chronic Rat Studies

Vinylidene Chloride

$$CI$$
 $C = C$



Decreased Survival in 100 ppm Females



| DOSE | Control | 25 ppm | 50 ppm | 100 ppm |
|--|---------|---------|---------|---------|
| SURVIVAL AT END OF STUDY (KAPLAN-MEIER) | 60.0% | 52.0% | 58.0% | 38.0% |
| SIGNIFICANCE (B) (LIFE TABLE) | P=0.046 | P=0.337 | P=0.709 | P=0.029 |

Chronic Study Results – Histopathological Findings

Systemic Neoplasms

Malignant mesothelioma (males), Mononuclear cell leukemia (females)

Thyroid gland (females)

C-cell adenoma, carcinoma

Kidney (males)

- Neoplasms: Renal tubular adenoma (step sections), renal tubular carcinoma
- Non-neoplastic: Renal tubular hyperplasia

Nose (males and females)

- Neoplasms: Respiratory epithelium adenoma (males)
- Non-neoplastic lesions: Turbinate atrophy, turbinate hyperostosis, chronic active inflammation, olfactory epithelial metaplasia, respiratory inflammatory polyp (females only)

Liver (males and females)

Non-neoplastic: chronic inflammation, diffuse fatty change, necrosis, cystic degeneration

Incidence of Malignant Mesotheliomas in Rats

| SYSTEMIC LESIONS | 0 ppm | 25ppm | 50ppm | 100ppm |
|--------------------------------------|-------|-------|-------|--------|
| Males | | | | |
| Mesothelioma, malignanta | 1** | 12** | 28** | 23** |
| Females | | | | |
| Mesothelioma, malignant ^b | 0 | 1 | 1 | 0 |

^{*} p<0.05; ** p < 0.01; (n=50)

- Grossly observed fluid in the abdomen and multiple nodules on the peritoneum particularly on the testicular tunics and epididymides
 - Lesions clearly associated with exposure to VDC, resulting from the occurrence of mesothelioma

^a Historical control same route 1/200 (range 0-2%), all routes 26/699 (range 0-8%)

b Historical control same route 0/200, all routes 0/700

Incidence of Thyroid Gland and Systemic Neoplasms in Female Rats

| THYROID | 0 ppm | 25 ppm | 50 ppm | 100 ppm |
|--|-------|--------|--------|---------|
| C-cell adenoma ^a | 3** | 4 | 6 | 11* |
| C-cell carcinoma ^b | 0 | 6* | 2 | 2 |
| C-cell adenoma or carcinoma ^c | 3** | 10* | 8 | 13** |
| SYSTEMIC | | | | |
| Mononuclear Cell Leukemiad | 10** | 11 | 13 | 25** |

^{*}p < 0.05, **p < 0.01; n=50

^a Historical control same route 13/200 (range 6-8%), all routes 81/690 (range 6-22%)

b Historical control same route 1/200 (range 0-2%), all routes 6/690 (range 0-7%)

^c Historical control same route 14/200 (range 6-8%), all routes 87/690 (range 6-22%)

d Historical control same route 58/200 (range 20-34%), all routes 165/700 (range 10-36%)

Incidence of Kidney Lesions in Males

| KIDNEY (Standard Single Sections) | 0 ppm | 25 ppm | 50 ppm | 100 ppm |
|--|-------|---------|---------|---------|
| Renal tubule, hyperplasia ^a | 0 | 1 [2.0] | 1 [1.0] | 1 [4.0] |
| Renal tubule, carcinomab | 0 | 2 | 1 | 1 |

^a Data presented as Incidence [Average severity grade]; 1=minimal, 2=mild, 3=moderate, 4=marked

^b Historical control same route 0/200; all routes 1/697 (range 0-2%)

Vinylidene Chloride-Induced Lesions in the Nose (Males)

| NOSE | 0 ppm | 25 ppm | 50 ppm | 100 ppm |
|--|---------|------------|------------|------------|
| Respiratory epithelium adenomab | 0** | 0 | 1 | 4 |
| Turbinate atrophy | 0 | 50 [2.2]** | 50 [3.2]** | 50 [3.8]** |
| Turbinate hyperostosis | 0 | 49 [2.1]** | 50 [2.6]** | 50 [2.9]** |
| Olfactory epithelium, respiratory metaplasia | 3 [1.0] | 49 [2.5]** | 49 [3.2]** | 48 [3.5]** |
| Olfactory epithelium, squamous metaplasia | 0 | 0 | 1 [2.0] | 5 [1.2]* |
| Respiratory epithelium, hyperplasia | 5 [1.6] | 8 [1.5] | 22 [2.5]** | 31 [2.3]** |
| Inflammation, chronic active | 9 [1.2] | 36 [2.0]** | 45 [2.7]** | 48 [3.2]** |
| Thrombosis | 4 [2.3] | 4 [3.0] | 11 [3.3]* | 7 [2.7] |

^{*} p < 0.05, **p < 0.01, n=50

^a Data presented as Incidence [Average severity grade]; 1=minimal, 2=mild, 3=moderate, 4=marked

b Historical control same route 0/198, all routes 0/697

Nonneoplastic Lesions in the Liver

| Males | 0 ppm | 25 ppm | 50 ppm | 100 ppm |
|-----------------------|----------|------------|------------|------------|
| Inflammation, chronic | 28 [1.0] | 46 [1.2]** | 46 [1.3]** | 44 [1.9]** |
| Fatty change, diffuse | 4 [2.0] | 19 [1.7]** | 18 [1.7]** | 26 [2.0]** |
| Necrosis | 2 [2.5] | 6 [2.8] | 8 [2.6]* | 6 [2.3] |
| Degeneration, cystic | 2 [2.0] | 5 [2.8] | 7 [1.9] | 12 [2.1]** |
| Females | | | | |
| Inflammation, chronic | 42 [1.0] | 48 [1.4]* | 49 [1.4]** | 48 [2.1]** |
| Fatty change, diffuse | 19 [1.2] | 30 [1.7]* | 26 [1.7] | 30 [2.0]** |
| Necrosis | 0 | 3 [1.7] | 5 [2.2]* | 11 [1.8]** |
| Degeneration, cystic | 0 | 2 [3.0] | 4 [2.3]* | 7 [2.7]** |

Data presented as Incidence [Average severity grade]; 1=minimal, 2=mild, 3=moderate, 4=marked p < 0.05, **p < 0.01, n=50

Evidence for Carcinogenic Activity in Rats

Males

- <u>Clear evidence</u> in male rats based on increased incidences of malignant mesothelioma.
- Increased incidences of renal tubule carcinomas and respiratory epithelium adenomas in the nose were also related to vinylidene chloride exposure

Females

- <u>Some evidence</u> in female rats based on increased incidences of Ccell adenoma or carcinoma in the thyroid gland and systemic mononuclear cell leukemia
- Occurrences of malignant mesothelioma may have been related to vinylidene chloride exposure

Treatment-Related Nonneoplastic Lesions in Rats

Males

- Kidney renal tubular hyperplasia
- Nose turbinate atrophy and hyperostosis, olfactory epithelial hyperplasia, olfactory epithelial respiratory and squamous metaplasia, chronic active inflammation
- Liver chronic inflammation, diffuse fatty change, necrosis, cystic degeneration

Females

- Nose turbinate atrophy and hyperostosis, olfactory epithelial respiratory and squamous metaplasia, respiratory epithelial hyperplasia, chronic active inflammation
- Liver chronic inflammation, diffuse fatty change, necrosis, cystic degeneration


Chronic Mouse Studies

Vinylidene Chloride

$$CI$$
 $C = C$





Survival in Mice Exposed to Vinylidene Chloride



- Decreased survival in males at 25 ppm and females at 6.25 and 25 ppm
- Increased survival in 6.25 ppm males

Body Weights in Mice Exposed to Vinylidene Chloride





- Mean body weights were decreased in 12.5 ppm males (10-17%) and 25 ppm males (10-24%)
- Mean body weights were decreased in 25 ppm females (12-23%)

Chronic Study Results – Histopathological Findings

Kidney

- Neoplasms: Renal tubular adenoma, carcinoma (males)
- Non-neoplastic: Renal tubular hyperplasia and cyst (males)

Liver

 Neoplastic: Hepatocellular adenoma and carcinoma (females), hepatocholangiocarcinoma (males and females)

Systemic

Hemangioma or Hemangiosarcoma (females)

Lungs

Alveolar/bronchiolar adenoma or carcinoma (females)

Small intestine

- Carcinoma
- Nose (males and females)
 - Non-neoplastic: Hyperostosis, turbinate atrophy; olfactory epithelial metaplasia, respiratory; hyaline droplet accumulation of olfactory epithelium; respiratory epithelial hyperplasia

Incidences of Kidney Lesions in Male Mice

| Neoplasms | 0 ppm | 6.25 ppm | 12.5 ppm | 25 ppm |
|--|-------|-----------|------------|------------|
| Renal tubule adenoma ^a | 0** | 5* | 19** | 10** |
| Renal tubule carcinomab | 0** | 7* | 31** | 18** |
| Renal tubule adenoma or carcinoma ^c | 0** | 11** | 37** | 27** |
| Nonneoplastic lesions | | | | |
| Renal tubule, hyperplasia | 0 | 8 [1.8]** | 22 [1.7]** | 16 [1.7]** |

^{*} p<0.05; ** p < 0.01; (n=50)

^a Historical control same route 0/298, all routes 8/944 (range 0-4%)

^b Historical control same route 0/298, all routes 3/944 (range 0-4%)

^c Historical control same route 0/298, all routes 11/944 (range 0-6%)

Incidences of Hemangioma and Hemangiosarcoma in Female Mice

| LIVER | 0ppm | 6.25ppm | 12.5ppm | 25ppm |
|--|------|---------|---------|-------|
| Hemangiosarcoma | 1** | 1 | 1 | 6* |
| ALL ORGANS | | | | |
| Hemangioma ^a | 0 | 2 | 2 | 2 |
| Hemangiosarcoma ^b | 4 | 4 | 4 | 9 |
| Hemangioma or Hemangiosarcoma ^c | 4* | 6 | 6 | 11* |

^{*} p<0.05; ** p < 0.01; (n=50)

^aHistorical control same route 0/300, all routes 5/950 (range 0-2%)

bHistorical control same route 21/300 (range 4-10%), all routes 50/950 (range 0-12%)

[°]Historical control same route 21/300 (range 4-10%), all routes 55/950 (range 2-14%)

Incidence of Liver Neoplasms in Mice

| Females | 0 ppm | 6.25 ppm | 12.5 ppm | 25 ppm |
|---------------------------------------|-------|----------|----------|--------|
| Hepatocellular adenoma ^a | 25* | 21 | 36* | 29 |
| Hepatocellular carcinomab | 8* | 14 | 12 | 17* |
| Hepatocellular adenoma or carcinomac | 28** | 30 | 37* | 38** |
| Hepatocholangiocarcinoma ^d | 0 | 1 | 1 | 2 |
| Males | | | | |
| Hepatocholangiocarcinoma ^e | 1 | 2 | 2 | 3 |

^{*} p<0.05; ** p < 0.01; (n=50)

^aHistorical control same route 105/300 (range 28-50%), all routes 378/948 (range 14-78%)

bHistorical control same route 44/300 (range 10-20%), all routes 152/948 (range 4-46%)

[°]Historical control same route 133/300 (range 32-56%), all routes 448/948 (range 20-82%)

dHistorical control same route 0/300, all routes 0/948

eHistorical control same route 2/299 (range 0-2%), all routes 10/949 (range 0-8%)

Incidences of Neoplasms in the Lung and Small Instestine of Female Mice

| LUNG | 0ppm | 6.25ppm | 12.5ppm | 25ppm |
|---|------|---------|---------|-------|
| Alveolar/bronchiolar adenoma | 3 | 4 | 2 | 2 |
| Alveolar/bronchiolar carcinoma ^a | 1* | 2 | 7* | 5 |
| Alveolar/bronchiolar adenoma or carcinoma | 4 | 5 | 9 | 7 |
| SMALL INTESTINE | | | | |
| Carcinomab | 1 | 1 | 1 | 3 |
| Adenoma or Carcinoma ^c | 2 | 1 | 2 | 4 |

^{*} p<0.05; ** p < 0.01; (n=50)

^aHistorical control same route 13/299 (range 0-10%), all routes 38/949 (range 0-14%)

bHistorical control same route 2/300 (range 0-2%), all routes 5/950 (range 0-2%)

^cHistorical control same route 4/300 (range 0-4%), all routes 10/950 (range 0-4%)

Nonneoplastic Lesions of the Nose

| Males | 0 ppm | 6.25 ppm | 12.5 ppm | 25 ppm |
|--|----------|------------|------------|------------|
| Turbinate atrophy | 0 | 46 [1.1]** | 46 [2.1]** | 47 [2.8]** |
| Hyperostosis | 1 [2.0] | 27 [1.3]** | 45 [2.1]** | 48 [2.2]** |
| Olfactory epithelium, hyaline droplet accumulation | 2 [1.0] | 5 [1.0] | 13 [1.3]** | 11 [1.3]** |
| Olfactory epithelium, respiratory metaplasia | 17 [1.2] | 39 [1.2]** | 47 [1.6]** | 48 [1.8]** |
| Females | | | | |
| Turbinate atrophy | 0 | 46 [1.0]** | 50 [2.3]** | 49 [2.8]** |
| Hyperostosis | 0 | 13 [1.2]** | 45 [2.0]** | 48 [2.2]** |
| Olfactory epithelium, hyaline droplet accumulation | 18 [1.6] | 18 [1.5] | 13 [1.4] | 32 [1.8]** |
| Olfactory epithelium, respiratory metaplasia | 3 [1.0] | 29 [1.1]** | 49 [1.6]** | 50 [1.9]** |
| Respiratory epithelium hyperplasia | 33 [1.1] | 41 [1.2] | 39 [1.5] | 43 [1.8]** |

Evidence for Carcinogenic Activity in Mice

Males

- <u>Clear evidence</u> in male mice based on increased incidences of renal tubule adenoma and carcinoma
- Increased incidences of hepatocholangiocarcinoma may have been related to vinylidene chloride exposure.

Females

- <u>Clear evidence</u> in female mice based on increased incidences systemic hemangioma or hemangiosarcoma (combined)
- Hepatocholangiocarcinoma and hepatocellular adenoma and carcinoma (combined) in the liver of female mice were also considered to be related to vinylidene chloride exposure.
- Increased incidences of alveolar/bronchiolar carcinoma in the lungs and carcinoma of the small intestine may have been related to treatment.

Treatment-Related Nonneoplastic Lesions in Mice

Males

- Kidney renal tubule hyperplasia, cysts
- Nose turbinate atrophy and hyperostosis, olfactory epithelium respiratory metaplasia, olfactory epithelium hyaline droplet accumulation

Females

 Nose - turbinate atrophy and hyperostosis, olfactory epithelium respiratory metaplasia, olfactory epithelium hyaline droplet accumulation, respiratory epithelium hyperplasia

END